- Home
- OABI vs LYEL Comparison
OABI vs LYEL Comparison
Compare OABI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- LYEL
- Stock Information
- Founded
- OABI 2012
- LYEL 2018
- Country
- OABI United States
- LYEL United States
- Employees
- OABI 114
- LYEL N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- LYEL Health Care
- Exchange
- OABI Nasdaq
- LYEL Nasdaq
- Market Cap
- OABI 239.0M
- LYEL 253.2M
- IPO Year
- OABI N/A
- LYEL 2021
- Fundamental
- Price
- OABI $1.65
- LYEL $17.11
- Analyst Decision
- OABI Strong Buy
- LYEL Hold
- Analyst Count
- OABI 3
- LYEL 3
- Target Price
- OABI $6.67
- LYEL $16.67
- AVG Volume (30 Days)
- OABI 525.9K
- LYEL 37.8K
- Earning Date
- OABI 11-04-2025
- LYEL 11-06-2025
- Dividend Yield
- OABI N/A
- LYEL N/A
- EPS Growth
- OABI N/A
- LYEL N/A
- EPS
- OABI N/A
- LYEL N/A
- Revenue
- OABI $23,027,000.00
- LYEL $60,000.00
- Revenue This Year
- OABI N/A
- LYEL N/A
- Revenue Next Year
- OABI $48.74
- LYEL N/A
- P/E Ratio
- OABI N/A
- LYEL N/A
- Revenue Growth
- OABI 6.05
- LYEL 11.11
- 52 Week Low
- OABI $1.22
- LYEL $7.65
- 52 Week High
- OABI $4.87
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- OABI 48.14
- LYEL 58.65
- Support Level
- OABI $1.64
- LYEL $16.48
- Resistance Level
- OABI $1.76
- LYEL $18.09
- Average True Range (ATR)
- OABI 0.10
- LYEL 1.20
- MACD
- OABI 0.01
- LYEL -0.16
- Stochastic Oscillator
- OABI 23.44
- LYEL 38.03
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.